Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 6/1997

Content (16 Articles)

ORIGINAL ARTICLE

A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11

Y. Onishi, Masao Oguro, Harutoshi Kizaki

ORIGINAL ARTICLE

Response of sensitive and resistant IgM immunocytomas to cis-diamminedichloroplatinum(II) does not correlate with the platination level or with the formation or removal of DNA adducts

Cornelis P. J. Vendrik, Anne Marie J. Fichtinger-Schepman, Wilhelmina C. M. van Dijk-Knijnenburg, W. H. de Jong, Anke C. E. van der Minnen, Gerard de Groot, Geert Frits Berends, P. A. Steerenberg

ORIGINAL ARTICLE

Preclinical antitumor activity of water-soluble paclitaxel derivatives

William C. Rose, John L. Clark, Francis Y. F. Lee, Anna Maria Casazza

ORIGINAL ARTICLE

Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan

H. Rosing, V. M. M. Herben, D. M. Gortel-van Zomeren, E. Hop, J. J. Kettenes-van den Bosch, W. W. Bokkel Huinink, J. H. Beijnen

ORIGINAL ARTICLE

In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers

David S. Alberts, Paul T. Fanta, Kelli L. Running, Laurence P. Adair Jr., Dava J. Garcia, Rosa Liu-Stevens, Sydney E. Salmon

ORIGINAL ARTICLE

Tissue distribution of transdermal toremifene

L. Soe, Gregory T. Wurz, Juhani U. Mäenpää, Gene B. Hubbard, Timothy B. Cadman, Valerie J. Wiebe, Alain P. Theon, M. W. DeGregorio

ORIGINAL ARTICLE

Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis

John L. Tonkinson, Philip Marder, Sherri L. Andis, Richard M. Schultz, Lynn S. Gossett, Chuan Shih, L. G. Mendelsohn

ORIGINAL ARTICLE

Preclinical pharmacokinetics of β-L-dioxolane-cytidine, a novel anticancer agent, in rats

Laura E. Moore, F. D. Boudinot, Chung K. Chu

ORIGINAL ARTICLE

Adrenal proteins bound by a reactive intermediate of mitotane

W. Cai, Raymond E. Counsell, David E. Schteingart, J. E. Sinsheimer, Alfin D. N. Vaz, Linda L. Wotring

CLINICAL TRIAL REPORT

High-dose toremifene in advanced renal-cell carcinoma

Michael M. Gershanovich, Vladimir M. Moiseyenko, Andrey V. Vorobjev, Hannu Käpylä, Juha Ellmén, Markku Anttila

SHORT COMMUNICATION

Interference by antifolate drugs in a folate competitive protein-binding assay

Anthea Hardcastle, Stephen Clarke, W. Aherne

SHORT COMMUNICATION

Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide

L. K. Webster, Martha E. Linsenmeyer, Danny Rischin, Maureen E. Urch, David M. Woodcock, Michael J. Millward

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine